12999 related articles for article (PubMed ID: 10590384)
21. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer.
Valtola R; Salven P; Heikkilä P; Taipale J; Joensuu H; Rehn M; Pihlajaniemi T; Weich H; deWaal R; Alitalo K
Am J Pathol; 1999 May; 154(5):1381-90. PubMed ID: 10329591
[TBL] [Abstract][Full Text] [Related]
22. Low-affinity nerve growth factor receptor (p75) in dermatofibrosarcoma protuberans and other nonneural tumors: a study of 1,150 tumors and fetal and adult normal tissues.
Fanburg-Smith JC; Miettinen M
Hum Pathol; 2001 Sep; 32(9):976-83. PubMed ID: 11567228
[TBL] [Abstract][Full Text] [Related]
23. VEGFR-3 in adult angiogenesis.
Witmer AN; van Blijswijk BC; Dai J; Hofman P; Partanen TA; Vrensen GF; Schlingemann RO
J Pathol; 2001 Nov; 195(4):490-7. PubMed ID: 11745682
[TBL] [Abstract][Full Text] [Related]
24. Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors.
Lymboussaki A; Partanen TA; Olofsson B; Thomas-Crusells J; Fletcher CD; de Waal RM; Kaipainen A; Alitalo K
Am J Pathol; 1998 Aug; 153(2):395-403. PubMed ID: 9708800
[TBL] [Abstract][Full Text] [Related]
25. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of anti-thrombomodulin antibody as a tumor marker for vascular neoplasms.
Manning T; Smoller BR; Horn TD; El Darouti M; Marzouk S; Hadidi HE; Ramadan S
J Cutan Pathol; 2004 Nov; 31(10):652-6. PubMed ID: 15491324
[TBL] [Abstract][Full Text] [Related]
27. Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas.
Itakura E; Yamamoto H; Oda Y; Tsuneyoshi M
J Surg Oncol; 2008 Jan; 97(1):74-81. PubMed ID: 18041747
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical expression and distribution of VEGFR-3 in malignant mesothelioma.
Filho AL; Baltazar F; Bedrossian C; Michael C; Schmitt FC
Diagn Cytopathol; 2007 Dec; 35(12):786-91. PubMed ID: 18008346
[TBL] [Abstract][Full Text] [Related]
29. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey.
Witmer AN; Blaauwgeers HG; Weich HA; Alitalo K; Vrensen GF; Schlingemann RO
Invest Ophthalmol Vis Sci; 2002 Mar; 43(3):849-57. PubMed ID: 11867607
[TBL] [Abstract][Full Text] [Related]
30. Growth hormone in vascular pathology: neovascularization and expression of receptors is associated with cellular proliferation.
Lincoln DT; Singal PK; Al-Banaw A
Anticancer Res; 2007; 27(6B):4201-18. PubMed ID: 18225592
[TBL] [Abstract][Full Text] [Related]
31. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.
Laakkonen P; Waltari M; Holopainen T; Takahashi T; Pytowski B; Steiner P; Hicklin D; Persaud K; Tonra JR; Witte L; Alitalo K
Cancer Res; 2007 Jan; 67(2):593-9. PubMed ID: 17234768
[TBL] [Abstract][Full Text] [Related]
32. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
[TBL] [Abstract][Full Text] [Related]
33. [Expression and clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in non-small cell lung carcinoma].
Lu ZQ; Li HG; Xie DR; Zhang HZ; Shen XM; Zeng YJ; Zeng H
Ai Zheng; 2005 Sep; 24(9):1132-5. PubMed ID: 16159440
[TBL] [Abstract][Full Text] [Related]
34. Interaction of rat tumor cells with blood vessels and lymphatics of the avian chorioallantoic membrane.
Papoutsi M; Sleeman JP; Wilting J
Microsc Res Tech; 2001 Oct; 55(2):100-7. PubMed ID: 11596155
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma.
Arinaga M; Noguchi T; Takeno S; Chujo M; Miura T; Uchida Y
Cancer; 2003 Jan; 97(2):457-64. PubMed ID: 12518370
[TBL] [Abstract][Full Text] [Related]
36. Lymphatic versus blood vascular endothelial growth factors and receptors in humans.
Partanen TA; Paavonen K
Microsc Res Tech; 2001 Oct; 55(2):108-21. PubMed ID: 11596156
[TBL] [Abstract][Full Text] [Related]
37. Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma.
Witte D; Thomas A; Ali N; Carlson N; Younes M
Anticancer Res; 2002; 22(3):1463-6. PubMed ID: 12168824
[TBL] [Abstract][Full Text] [Related]
38. Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate.
Ravindranath N; Wion D; Brachet P; Djakiew D
J Androl; 2001; 22(3):432-43. PubMed ID: 11330643
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma.
Kojima H; Shijubo N; Yamada G; Ichimiya S; Abe S; Satoh M; Sato N
Cancer; 2005 Oct; 104(8):1668-77. PubMed ID: 16116610
[TBL] [Abstract][Full Text] [Related]
40. Vascular endothelial growth factor: acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803.
Tian X; Song S; Wu J; Meng L; Dong Z; Shou C
Biochem Biophys Res Commun; 2001 Aug; 286(3):505-12. PubMed ID: 11511087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
